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1. Introduction 
The acid-stable antitryptic activity of bovine 
serum is separated by gel chromatography into two 
fractions with apparent relative molecular mass (M,) 
of 30 000 and M, 8000. For the human system we 
have demonstrated that the low molecular we&t 
inhibitor M, 8000 (HI-g) stems from the physiolog- 
ical inhibitor M, 30 000 (HI-30) present in human 
serum and urine (l-3). The inhibitor HI-8 represents 
the antitryptic active domain. In vitro, the active 
domain is released from the parent inhibitor HI-30 
by limited tryptic proteolysis via an intermediate 
withM, 14 000 (HI-14). Based on these results in the 
human system, we attributed the two fractions we 
obtained from bovine serum to an analogous parent 
inhibitor with M, = 30 000 (BI-30) and an active 
domain with anM, 8000 (BI-8). However, a N-termi- 
nal amino acid sequence determination proved that 
we had isolated a new Kunitz-type inhibitor from 
bovine serum. The inhibitor differs significantly in 
amino acid sequence from the active domains derived 
from the physiological inhibitors HI-30 and BI-30 
present in human and bovine serum. The primary 
structure reveals pronounced homology to the basic 
trypsin-kallikrein inhibitor from bovine tissues [4]. 
The inhibitor shows no immunological cross-reactiv- 
ity with the tissue inhibitor. 
Here we present the primary structure of the new 
Kunitz-type inhibitor. The sequence allows a predic- 
tion of kallikrein inhibition. 
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2. Materials and methods 
2.1. Chenlicals and reagerzts 
Trypsin treated with N-p-toluolsulfonyl-L-phenyl- 
alanine-chloromethyl ketone (TPCK), N-a-benzoyl-L- 
arginine-p-nitroanilide was obtained from Merck, 
Darmstadt. Porcine kallikrein and antibodies directed 
to the bovine basic pancreatic trypsin-kallikrein 
inhibitor (Trasylol@) were gifts from Bayer AG, 
Elberfeld. Human plasma kallikrein was isolated 
according to [.5]. Human urinary kallikrein was iso- 
lated as in [6]. CNBr-activated Sepharose and 
Sephadex G-75 was from Pharmacia, Freiburg. Bio- 
Gel P-30 was from Bio-Rad, Gauting. Phenylene 
diisothiocyanate was from Eastman, Heidelberg. 
Phenylisothiocyanate and CNBr was from Fluka, 
Neu-Ulm. N-cr-Benzoyl-arginine-ethyl ester and car- 
bobenzoxy-L-Tyr-p-nitrophenyl ester were from 
Serva, Heidelberg. D-Val-L-Leu-L-Arg-p-nitroanilide 
was a gift from AB Kabi, Mdlndal. Succinyl-L-Phe-p- 
nitroanilide was from Boehringer, Mannheim. All 
other reagents were of analytical grade and used as 
purchased. 
1.2.. Isolation of the inhibitor from bovine serum 
Bovine serum (100 1) was treated with 70% HC104 
to reach a final cont. 3% HC104. The supernatant was 
neutralized with 5 N KOH. KC104 was removed and 
the supernatant was concentrated to 5 1 by rotary 
evaporation. The solution contained an antitryptic 
activity of 560 inhibitor units. The pH of the inhibi- 
tor solution was adjusted with 2 N NaOH at pH 7.8. 
Trypsin-Sepharose was added to the solution until 
the antitryptic activity was completely complexed. 
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The immobilized enzyme-inhibitor complex was 
washed with 5 1 of 0.2 M triethanolamine/HCl buffer 
(pH 7.8) 0.2 M in NaCl. The inhibitory active mate- 
rial was released from the support by addition of 0.2 
N KCl/HCl solution (pH 1 S). The recovery of anti- 
tryptic activity was 80%. The solution was concen- 
trated by ultrafiltration on an Amincon UN-2 mem- 
brane and was subjected to gel filtration on Sephadex 
G-75. The antitryptic activity of the eluate was deter- 
mined as in [7]. Three active fractions were identified. 
The fraction eluting with Mr 8000 was concentrated 
and desalted on Bio-Gel P-2 with 0.4 M ammonium 
acetate (pH 6.8) and was lyophilized repeatedly. 
2.3. Amino acid sequence determination 
2.3.1. CNBr-cleavage 
Inhibitor (1 hmol) was dissolved in concentrated 
formic acid, 1 M in CNBr. The concentration was 
adjusted to 80% formic acid by addition of water to 
attain 1 ml final vol. The reaction was allowed to 
proceed for 24 h at 20°C in the dark. The fragment 
peptides were size-fractionated on a column of Bio- 
Gel P-30 minus 400 mesh developed with 80% formic 
acid. Amino acid analysis was performed after hydro- 
lysis of peptides with 5.7 N HCl for 24 h at 105’C or 
60 min at 16O’C. Hydrolysates were analyzed on a 
Durrum D-500 (Palo, Alto). The ~~-terminal residues 
of peptides were determined by the dansylation 
method [8]. 
2.3.2. Immobilization of the i~bitor and the 
fragment peptides on activated porous glass 
supports 
The inhibitor was attached via e-amino groups to 
the ~-phenylenediisothiocyanate derivative of 3-ami- 
nopropyl glass [9]. Reduction and aminoethylation 
of the cystine bridges was performed at the support- 
fixed inhibitor [IO]. The CNBr-peptides with C-ter- 
minal homoserine were attached via the Iactone deriv- 
ative to 3-aminopropyl glass. The C-terminal peptide 
of the inhibitor, lacking homoserine was attached via 
the carboxylic group of the C-terminal Ala to 3-ami- 
nopropyl glass. The carboxylic function was activated 
by N-ethyl#-dimethylaminopropylcarbodiimide + 
HCl and N-hydroxybenzotriazol [ 111. Edman degra- 
dation was performed by a home-built solid phase 
sequencer closely related to the one originally designed 
by Laursen [ 12,131. The degradation program, the 
processing of the released anilinothiazolinones and 
the ident~~cation of the phenylt~ohydantoins is 
detailed in { 141. 
2.4. Assays ofenzyme and inhibitor activity 
The inhibition of trypsin was tested with N-or-ben- 
zoyl-D,LArg-p-nitroanilide as substrate [7]. Inhibition 
of porcine pancreatic kallikrein was tested with N-a- 
benzoyl-L-Arg-ethyl ester. Inhibition of kallikrein 
from human plasma was tested with N-o-benzoyl- 
Pro-Phe-Arg-p-nitroanilide [ 151. Kallikrein from 
human urine was assayed with N-carbobenzoxy-L- 
Tyr-p-nitrophenyl ester [r‘6] and D-Val-L-Leu-L- 
Arg-p-nitroanilide. The values obtained were corrected 
for spontaneous hydrolysis. The inhibition constants 
were calculated according to [I 71. 
3. Results and discussion 
3.1. characterization f the acid stable proteinase 
inhibitors from bovine serum 
The supernatant of bovine as well as of human 
serum contains antitryptic activity after treatment 
with HC104. The ~titryptic activity is separated by 
gel chromatography into two fractions for bovine 
serum with J4, 30 000 and M, 8000. Only one frac- 
tion with Mr. 30 000 is yielded in human serum 
(fig.lA,C). We have demonstrated that the human 
inhibitor is related to the inter-o-trypsin inhibitor 
[l-3]. Limited tryptic proteolysis of the human 
inhibitor leads via an intermediate with&f, 14 000 
(HI-14) to an antitryptic active domain withM, 
8000 (HI-8). Limited proteolysis of the bovine anti- 
tryptic active fractions results in a similar pattern of 
active fractions. The distribution of the fractions. 
however, is strikingly different, despite constant 
experimental conditions. In the human system, only 
small amounts of the active domain with Mr 8000 are 
obtained, whereas in the bovine system this fraction 
is considerably more pronounced (fig,lB,D). 
Until these experiments, the bovine active fraction 
with Mr 8000 had been considered to be a derivative 
released via intermediates from the bovine inter-cu- 
trypsin inhibitor, although the amount of inhibitoric 
activity was puzzling when compared with the human 
system. 
To complete the primary structure of the active 
domain from the bovine inter-e+trypsin inhibitor, the 
material corresponding to Mr 8000 was subjected to 
Edman degradation. The N-terminal sequence indi- 
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Fig.1. Gel filtration on columns of Sephadex G-75: dlmen- 
sion 200 X 3 cm; buffer 0.05 M borate (pH 8.01, 0.2 N NaCl; 
fraction vol. 15 ml; antitryptic activity (ordinate) was detected 
from aliquots as in [7]. (A) Supernatant of bovine serum 
after treatment with HClO,; (B) bovine inhlbltors Isolated via 
trypsu-Sepharose; (C) supernatant of human serum after 
treatment with HCIO,; (D) human inhibitors isolated via 
trypsin-Sepharose. 
cated that we had, in fact, isolated from bovine serum 
a new Kunitz-type inhibitor very closely related to 
the well known bovine pancreatic trypsin-kallikrein 
inhibitor [4], yet quite different to the antitryptic 
active domain derived from the bovine inter-cu-trypsin 
inhibitor [18]. 
3.2. Amino acid sequence determination 
The pattern for the sequence determination and 
the peptide alignment is presented in fig.2. The first 
step consisted in immobilizing the inhibitor at the 
activated support via the e-amino groups of lysines 
within the polypeptide chain and the a-amino group 
of the N-terminus. The coupling yield was almost 
quantitative. Reduction and aminoethylation of the 
three disulfide bridges was performed using the sup- 
port-fixed inhibitor. This procedure is time-saving 
and limits the possible gaps in the sequence. A modi- 
fication of cysteines to aminoethylcysteine prior to 
the immobilization generates additional sidechain 
amino groups, i.e., additional anchor-points and pos- 
sible gaps in the sequence. Furthermore, gaps must 
be interpreted as lysine or aminoethylcysteine, thus 
leading to ambiguities. In contrast, gaps obtained by 
the selected modification method may be attributed 
exclusively to lysine residues in the chain. The Edman 
degradation run up to aminoethylcysteine in pos. 40. 
The N-terminal Thr remained bound to the support. 
To complete the sequence, the potential of the 
solid phase method of coupling selectively CNBr- 
peptides was utilized. From the degradation of the 
whole inhibitor one Met was settled at pos. 20 fol- 
lowed by Ile (fig.2). The bovine pancreatic trypsin 
inhibitor (BPTI) as well as the inhibitor from cow 
colostrum [4,19] contains a Met rather close to the 
C-terminus. Therefore it was tempting to expect a 
Met in the serum inhibitor too. CNBr-cleavage of the 
serum inhibitor resulted, in fact, in 3 fragment pep- 
tides after gel chromatography on Bio-Gel P-30. The 
largest fragment, B2, is characterized by a N-terminal 
Ile. The peptide Bl has a N-terminal Thr. The degra- 
dation of this peptide established the sequence already 
obtained from the previous degradation. Degradation 
of the peptide B2 established the second Met in pos. 
54. The remaining hexapeptide B3 lacks homoserine 
and must be attributed, therefore, to the C-terminus 
of the inhibitor. Now the alignment of the fragment 
peptides was easy. Some ambiguite remained for res. 
33 occupied by Glu in contrast to BPTI where this 
residue is Gln. The possibility that the HC104-treated 
serum inhibitor has been deamidated almost com- 
pletely can not be excluded, 
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10 20 
T~~r-G~u-~r~-Pro-~sp-Phe-Cys-Leu-Glu-Pro-Pro-Tyr-Thr-Gly-Pr~-c~~-L~~-Al~-Al~-~~~- 
+ DITC 
-......................................................................Bl . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ..~ 
30 40 
I~e-Arg-Tyr-Phe-Tyr-Asn-Ala-Lys-Ala-Gly-Phe-Cys-Glu-Thr-Phe-val-Tyr-Gly-Gly-Cys- 
DITC - 
-................................................................... c2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
50 60 
Arg-Ala-Lys-Ser-Asn-Asn-Phe-Lys-Ser-Ala-Glu-Asp-Cys-Met-Arg-Thr-Cys-Gly-G~y-A~a 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ...> -............... E3..................~ 
Fig.2. Pattern for amino acid sequence determination and alignment of peptides. DITC designates the degradation performed with 
the whole inhibitor immobilized to the p-phenylenediisothiocyanate derivative of 3-aminopropyl glass. B destgnates peptides 
generated by CNBr-cleavage. 
3.3. Inhibitory properties and immunological 
relationship 
The sequence of the bovine serum inhibitor indi- 
cates a strong structural homology to the known 
Kunitz-type inhibitor from bovine tissues [4]: 
B&8+ TERPDFCLEPPYTCPCKAAplRYFYN 
RPTI RPDFCLEPPYTGPCKARIIRYFYN 
61-E+ AKAGFCETFVYGGCRAnSNNFKSAED 
BPTI AKAGLCQTFVYGGCRAKRNNFKSAED 
51-E+ CMRTCGGA 
BPTI C II R T C G GA 
Only 4 or 5 residues are changed. The number of 
replacements is dependent on the ambiguity associated 
with residue 33. The homologous Kunitz-type inhibi- 
tors released from the human and bovine inter-c+ 
trypsin inhibitor are ‘monovalent’ inhibitors. Inhibi- 
tion of chymotrypsin and plasmin is weak. BPTI is a 
broad specific inhibitor. A comparison of the bovine 
serum inhibitor with BPTI shows that inhibition of 
trypsin, chymotrypsin, plasmin, pancreatic and urinary 
kallikrein are almost identical. The Ki-values for por- 
cine pancreatic kallikrein-inhibitor complexes are 
compared in fig.3. Plasma kallikrein inhibition is 
weak, similar to BPTI. 
The structure-activity relationships of some 
Kunitz-type inhibitors and kallikreins from different 
sources was investigated in [20]. Inhibitors with basic 
residues in positions 17 and 39 (numbering according 
to BPTI) or 17 and 19 are strong inhibitors for glan- 
dular kallikreins. Inhibitors lacking the basic residues 
either in position 39 and/or 17 but possessing a basic 
residue in position 19 are still fairly strong kallikrein 
inhibitors. The Kunitz-type inhibitor from cow colos- 
trum and the inhibitors derived from the human 
inter+trypsin inhibitor have no basic residue in any 
of these positions and do not form complexes with 
kallikreins. In the bovine serum inhibitor position 39 
is occupied by Arg and is, in fact, a potent kallikrein 
inhibitor. 
The bovine active domain released from the inter- 
cY-trypsin inhibitor however, has a basic residue in 
pos. 39, Lys, but is no kallikrein inhibitor. One may 
conclude that in those cases when pos. 39 is respon- 
sible for kallikrein inhibition, this residue must not 
only be basic, but Arg. 
The serum inhibitor shows no immunological 
cross-reactivity to antibodies directed to BPTI. Both 
inhibitors differ due to the altered sequence in the 
contact area to kallikrein [24]. The result affirms the 
assumption that the sequence, i.e., the contact area 
surrounding the active site in pos. 1.5, common to all 
inhibitors, is the main antigeneity-determining site. 
The inhibitory properties of the bovine serum 
inhibitor were predicted from the elucidated sequence 
in connection with the pronounced homology to 
known and well-characterized Kunitz-type inhibitors. 
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InhIbItor Source 12 13 14 15 16 I.7 18 19 20 34 35 36 37 38 39 40 K,xIO‘~:M] 
BPTI bovine lung -Gly-Pro-Cys-Lys-Ala-AqI;-TIP-TLF-Arg- ---- -Val-Tyr-Gly-Gly-Cys-ARG-Ala- 0.8 
SAI-5-11 sea anemone -Gly-Pro-Cys-Arg-Ala-j!Q&Phe-PRO_Arg- ---- -Ile-Tyr-Gly-Gly-Cys-ARG_Gly- 0.8 
NNV-II snake venom -Gly-Leu-Cys-Lys-Ala-ARF-fie-A~~-~er- ---- -Ile-Tyr-Gly-Gly-Cys-GLY_Gly- 1.1 
HHV-II snake venom -Gly-Leu-Cys-Lys-Ala-TYQ-Ile_PRG-S er- ---- -Ile-Tyr-Gly-Gly-Cys-GLy-Gly- 8.3 
HPIK snail -Gly-Pro-Cys-Lys-Ala-CEQ-Phe-Af?G-Gln- ---- -Ile-Tyr-Gly-Gly-Cys-ARG_Gly- 27.7 
CT1 colostrum 
BI-8& 
-G~~-P~o-C~S-L~S-A~~-ALA-L~U-LE[.~-A~-~- ---- -Thr-Tyr-Gly-Gly-Cys-GLN_Gly- ---- 
bovlne serum -Gly-Pro-Cys-Lys-Ala-AL4-net_ILE-Arg- ---- -Val-Tyr-Gly-Gly-Cys-ARG_Ala- 12.0 
HI-14-I human ITI -Gly-Pro-Cys-Met-Gly-$4ET-Thr-?FfJ-Arg- ---- -Gin-Tyr-Gly-Gly-Cys-MET-Gly- ---- 
HI-14-11 human IT1 -Gly-Pro-Cys-Arg-Ala-pi.lE-Ile-GL',/-Leu- ---- -Pro-Tyr-Gly-Gly-Cys-GLli-Gly- ---- 
61-14-1 bovine IT1 -Gly-Pro-Cys-Leu-Gly-LEI~-Phe-LYS-drg- ---- -Leu-Tyr-Gly-Gly-Cys-MET-Gly- ---- 
BI-14-11 bovine ITI -Gly-Pro-Cys-Arg-Ata-PHE_Ile- ? - ? - ---- -Ser-Tyr-Gly-Gly-Cys-/Js-Gly- ---- 
Fig.3. Amino acid sequences of the proposed contact areas of structurally homologous Ku&z-type proteinase inhibitors with 
porcine pancreatic kallikrein in the enzyme-inhibitor complex and Ki values of the complexes. Numbering of residues is accord- 
ing to BPTI. 
Ab&revia?ionsr BPTI, trypsin-kalBkrein ~hibitor from bovine tissues [4.20]; SAI-S-II, trypsin-kallikrein ~hibitor from sea 
anemone [21]; NNV-II and HHV-II, trypsin-kallikrein inhibitor from snake venom [22]; HP1 K, trypsin-kallikrein inhibitor from 
Helix pomatiu 1231; CTI, trypsin inhibitor from cow colostrum [19]. BI-8+, trypsin-kallikrein inhibitor from bovine serum. 
HI-14-1, N-terminal Kunitz-type domain of the trypsin inhibitor released from the inter-or-trypsin inhibitor, inactive [2]; III-14-11, 
active domain of the inhibitor [J 1; BI-14-1, N-terminal Kunitz-type domain released from the bovine inter*-trypsin inhibitor, 
inactive [ 181; BI-14-H active domain of the inhibitor 
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